Clinical Trial Update: The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer [Phase 3]

View source ↗

Summary

The DISTAL-2 Phase 3 trial evaluating docetaxel, alone or in combination, as second-line therapy for advanced non-small cell lung cancer has been terminated. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 3 | Status: TERMINATED